Loading stock data…
GHRS
$20.71+0.18 (+0.88%)
After Hours$20.89+0.18 (+0.87%)· Last close May 1
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GH Research PLC in the Healthcare sector is trading at $20.71. The stock is currently 16% below its 52-week high of $24.66, remaining 41.6% above its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why GHRS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$20.71
Potential Upside
5%
Whystock Fair Value$21.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.25%
Volume
Today's trading volume
121,724
Recent News
FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.
Compass Pathways, the developer of synthetic psilocybin, announced it had received a government voucher.
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administr
‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar
The White House is in for a trip.
How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying
Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the